Biocon expects recovery in generics business in FY23:


The pharma company said that it expects recovery in generics business in FY23.

Margin improvement in biosimilars aided by developed markets. Expect improvement in Semglee market share in CY22. Near-term focus is COVID-19 vaccines with serum.

See the biosimilar business gaining momentum. No visibility on when the inspection for Bevacizumab will be done. Have asked US FDA to even consider a remote inspection for Bevacizumab.

News Source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button